Last $1.50 USD
Change Today +0.0047 / 0.31%
Volume 4.9K
PFSCF On Other Exchanges
Symbol
Exchange
OTC US
Toronto
Frankfurt
As of 8:10 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

prometic life sciences inc (PFSCF) Snapshot

Open
$1.44
Previous Close
$1.50
Day High
$1.50
Day Low
$1.44
52 Week High
11/18/14 - $1.96
52 Week Low
04/29/14 - $0.79
Market Cap
821.4M
Average Volume 10 Days
5.6K
EPS TTM
--
Shares Outstanding
547.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PROMETIC LIFE SCIENCES INC (PFSCF)

Related News

No related news articles were found.

prometic life sciences inc (PFSCF) Related Businessweek News

No Related Businessweek News Found

prometic life sciences inc (PFSCF) Details

ProMetic Life Sciences Inc., a biopharmaceutical company, develops bioseparation, plasma-derived therapeutics, and small-molecule drugs. The company also offers its technologies for large-scale drug purification, drug development, proteomics, and the elimination of pathogens; and develops small molecule therapeutics products targeting unmet medical needs in the fields of fibrosis, anemia, cancer, and autoimmune disease, as well as plasma-derived therapeutics in orphan drug indications. It operates in two segments, Therapeutics and Protein Technology. The Therapeutics segment’s lead product includes PBI-4050, which targets unmet medical needs, such as the treatment of fibrosis in patients with chronic kidney diseases and certain cancers, and the side effects associated with chemotherapy. This segment also develops PBI-4419, an anti-fibrotic and anti-inflammatory compound for kidney injury and chronic kidney diseases; and PBI-1402, a drug candidate for the treatment of anemia indications. The Protein Technology segment provides plasma protein purification system, a solution for the extraction and purification of therapeutic proteins from human plasma; bioseparation products based on applications of its patented Mimetic Ligand technology for various biopharmaceutical companies; and prion capture/pathogen removal technology platform that improves the safety profile of blood products and blood-derived therapeutics. The company was formerly known as Innovon Life Sciences Holdings Limited and changed its name to ProMetic Life Sciences Inc. in May 1998. ProMetic Life Sciences Inc. was founded in 1992 and is headquartered in Laval, Canada.

Founded in 1992

prometic life sciences inc (PFSCF) Top Compensated Officers

Chief Executive Officer, President and Non-In...
Total Annual Compensation: C$435.0K
Chief Financial Officer and Chief Operating O...
Total Annual Compensation: C$322.3K
Chief Executive Officer of ProMetic BioScienc...
Total Annual Compensation: C$238.5K
General Counsel and Corporate Secretary
Total Annual Compensation: C$197.0K
Senior Vice President of Product & Asia Pacif...
Total Annual Compensation: C$283.6K
Compensation as of Fiscal Year 2013.

prometic life sciences inc (PFSCF) Key Developments

ProMetic Life Sciences Inc. Announces PBI-4050 Cleared to Commence Clinical Trials in Patients with Metabolic Syndrome and Associated Type 2 Diabetes

ProMetic Life Sciences Inc. reported that its orally active lead drug candidate, PBI-4050, has been approved to commence the clinical trial in patients suffering from metabolic syndrome and resulting Type 2 diabetes, following the CTA clearance by Health Canada. Metabolic syndrome is a major risk factor for cardiovascular disease and for Type 2 diabetes, and consists of the constellation of central (truncal) obesity, high blood triglycerides, low HDL (good) cholesterol, elevated blood pressure, and elevated blood glucose. ProMetic has successfully completed its PBI-4050 Phase I clinical trial in 40 healthy volunteers, in which it was found to be safe and well tolerated, with no serious adverse events. The Corporation has also started enrolling patients with diabetic kidney disease (DKD) in the multi-dose part of the Phase Ib trial and is expected to report results thereon by the end of the first quarter of 2015.

ProMetic Life Sciences Inc. Provides fourth quarter of 2014 Clinical Development and Commercial Milestones Update

ProMetic Life Sciences Inc. provided tan update on its clinical development and commercial milestones scheduled for completion in fourth quarter of 2014. The Investigational New Drug (IND) application for ProMetic's intravenous immunoglobulin (IVIG) was filed in December 2014 with the American Food and Drug Administration (FDA) and patients' enrolment is expected to commence during this quarter. The enrolment of patients for the Plasminogen Phase 1 clinical trial is progressing as expected. No serious adverse events were reported in the initial part of the PBI-4050 phase 1b/II trial in patients with Diabetic Kidney Disease (DKD). Finally, the completion of the previously announced license and strategic agreement with Generium on December 21, 2014 as well as the achievement of a development milestone in late December 2014 alone contributed approximately $9 Million to fourth quarter of 2014.

ProMetic Life Sciences Inc. and GENERIUM Pharmaceuticals Sign Agreement for Plasma-Derived Biopharmaceuticals

ProMetic Life Sciences Inc. has entered into definitive agreement with GENERIUM Pharmaceuticals for plasma-derived biopharmaceuticals to be manufactured and commercialized in Russia and Commonwealth of Independent States, or CIS. GENERIUM and ProMetic create global partnership for the co-development and commercialization of two plasma-derived coagulating factors. The strategic alliance includes the granting of manufacturing rights by ProMetic to GENERIUM for several plasma-derived biopharmaceuticals using ProMetic's proprietary PPPS technology. In addition, ProMetic will provide training and technical support to manufacture said plasma-derived biopharmaceuticals in a facility to be built and operated by GENERIUM, in Russia. The design of the GENERIUM plasma purification facility will be based on ProMetic's own Laval facility and will have a plasma processing capacity of upto 600,000 litres per year. Construction of facility has already commenced and is expected to be completed by 2017. GENERIUM will fully fund the construction and operating costs of its new cGMP PPPS facility. Once GENERIUM's plasma purification facility becomes operational, both GENERIUM's and ProMetic's facilities may complement each other as contract manufacturing organizations on specific biopharmaceutical products. ProMetic will also supply the required affinity resins for the PPPS based Russian facility and mid-single digit royalties will be paid by GENERIUM to ProMetic on sales of the biopharmaceutical products in the Russian /CIS markets. The strategic alliance also includes two coagulation factors that will be co-developed and commercialized globally with both parties equally sharing net profits from sales.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PFSCF:US $1.50 USD +0.0047

PFSCF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PFSCF.
View Industry Companies
 

Industry Analysis

PFSCF

Industry Average

Valuation PFSCF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 50.5x
Price/Book 29.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 49.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROMETIC LIFE SCIENCES INC, please visit www.prometic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.